Related Experiment Video

Updated: Jun 7, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Preclinical and clinical activity of ATP mimetic JAK2 inhibitors

Martha Wadleigh1, Ayalew Tefferi

  • 1Leukemia Program, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA. Martha_wadleigh@dfci.harvard.edu

Clinical Advances in Hematology & Oncology : H&O
|October 23, 2010
PubMed

Insights

Janus kinase 2 (JAK2) inhibitors show promise for myeloproliferative neoplasms, improving symptoms like enlarged spleen and abnormal blood counts. Further research is needed to fully understand their long-term effects on bone marrow fibrosis and JAK2 allele burden.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • The JAK2V617F mutation is a common driver in myeloproliferative neoplasms (MPNs).
  • This discovery has spurred interest in targeted therapies, specifically small molecule JAK2 inhibitors.

Purpose of the Study:

  • To review the current clinical development and therapeutic use of JAK2 inhibitors in MPNs.
  • To assess the demonstrated clinical benefits and limitations of these targeted therapies.

Main Methods:

  • Review of ongoing clinical trials for JAK2 inhibitors in primary myelofibrosis (PMF) and post-polycythemia vera (PV)/essential thrombocythemia (ET) myelofibrosis.
  • Evaluation of drug activity in PV and ET patients.

Main Results:

  • Clinical benefits observed include reduced splenomegaly, improved constitutional symptoms, and controlled leukocytosis.
  • Activity against erythrocytosis, thrombocytosis, pruritus, and splenomegaly has been noted in PV and ET.
  • Modest effects on bone marrow fibrosis and JAK2 allele burden have been reported.

Conclusions:

  • Current JAK2 inhibitor trials represent an early stage of therapeutic development for MPNs.
  • It is premature to draw definitive conclusions regarding comparative drug activity or toxicity.
  • Further research and clinical trials are essential to fully elucidate the role of JAK2 inhibitors in MPN management.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...